Kassis Imad, Srugo Isaac, Srur Suzan, Horowitz Yosef, Almagor Tal, Wolf Dana, Kra-Oz Zipi, Kennes Yoram, Rishpon Shmuel, Miron Dan
Pediatric Infectious Disease Unit, Meyer Children Hospital, Haifa, Israel.
Harefuah. 2009 Nov;148(11):748-51, 795, 794.
Acute bronchiolitis (AB) is a significant indication for hospitalization during the winter period. Underlying conditions increase risk for severe manifestations.
To estimate the burden and outcomes of AB in northern Israel.
A prospective study was performed between 1.12.2005 - 31.3.2006. Previously healthy children younger than 2 years of age, hospitalized with the diagnosis of AB, in three hospitals in northern Israel, were included in this study.
Overall, 465 children (93%) out of 500 children who were hospitalized due to AB and comprised 18% of all hospitalizations during the study period, were included. A pathogen was identified in 91% of cases. A single pathogen was identified in 243 (52%) cases; 2-4 pathogens were found in 176 (39%) children. Common pathogens were respiratory syncytial virus (RSV) and Rhinovirus in 346 (75%) and 129 (28%), of which 192 (41%) and 37 (8%) were sole pathogens respectively. Complete data were available for 390 (82%) children, of whom 78% were younger than 6 months. Patients were hospitalized for 4 +/- 4.4 days; 15 children were treated in intensive care. There was one mortality. An X-ray was performed in 94% of cases. Most children were treated with multiple regimens including intravenous fluids, O2 supplement, physiotherapy, bronchodilators, steroids and antibiotics. Bronchiolitis was attributed to 18% of hospitalizations. On a national scale, assuming that the policy of hospitalization is similar, 4100 children were hospitalized due to AB. This reflects 4% of all hospitalized children a year in Israel and attributing to 16,400 hospitalizations.
AB is associated with a huge burden, during a short period of the year, on pediatric departments, mainly attributed by infants younger than 6 months of age. The development of effective vaccine against RSV may significantly reduce the burden of morbidity.
急性细支气管炎(AB)是冬季住院的一个重要指征。基础疾病会增加出现严重症状的风险。
评估以色列北部AB的负担及结局。
于2005年12月1日至2006年3月31日进行了一项前瞻性研究。纳入以色列北部三家医院中因AB诊断而住院的2岁以下既往健康儿童。
总体而言,500名因AB住院的儿童中有465名(93%)被纳入研究,占研究期间所有住院病例的18%。91%的病例中鉴定出病原体。243例(52%)中鉴定出单一病原体;176名(39%)儿童中发现2至4种病原体。常见病原体为呼吸道合胞病毒(RSV)和鼻病毒,分别占346例(75%)和129例(28%),其中192例(41%)和37例(8%)分别为单一病原体。390名(82%)儿童有完整数据,其中78%小于6个月。患者住院4±4.4天;15名儿童在重症监护室接受治疗。有1例死亡。94%的病例进行了X光检查。大多数儿童接受了多种治疗方案,包括静脉输液、吸氧、物理治疗、支气管扩张剂、类固醇和抗生素。细支气管炎占住院病例的18%。在全国范围内,假设住院政策相似,4100名儿童因AB住院。这占以色列每年所有住院儿童的4%,导致16400次住院。
AB在一年中的短时间内给儿科带来巨大负担,主要由6个月以下婴儿所致。开发有效的RSV疫苗可能会显著减轻发病负担。